(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Adial Pharmaceuticals's earnings in 2025 is -$8,449,950.On average, 5 Wall Street analysts forecast ADIL's earnings for 2025 to be -$14,323,675, with the lowest ADIL earnings forecast at -$18,610,736, and the highest ADIL earnings forecast at -$12,147,402. On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$13,024,896, with the lowest ADIL earnings forecast at -$16,899,404, and the highest ADIL earnings forecast at -$8,709,458.
In 2027, ADIL is forecast to generate -$14,917,402 in earnings, with the lowest earnings forecast at -$16,899,404 and the highest earnings forecast at -$12,605,794.